Core Laboratories (CLB) Expected to Announce Quarterly Sales of $171.06 Million

Analysts predict that Core Laboratories (NYSE:CLB) will report sales of $171.06 million for the current quarter, according to Zacks. Two analysts have made estimates for Core Laboratories’ earnings, with the highest sales estimate coming in at $171.40 million and the lowest estimate coming in at $170.71 million. Core Laboratories reported sales of $157.81 million in the same quarter last year, which indicates a positive year-over-year growth rate of 8.4%. The company is scheduled to issue its next earnings report on Wednesday, April 18th.

On average, analysts expect that Core Laboratories will report full year sales of $171.06 million for the current fiscal year, with estimates ranging from $698.41 million to $740.36 million. For the next financial year, analysts anticipate that the company will post sales of $771.56 million per share, with estimates ranging from $745.96 million to $797.62 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Core Laboratories.

Core Laboratories (NYSE:CLB) last released its quarterly earnings data on Wednesday, January 31st. The oil and gas company reported $0.58 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.58. Core Laboratories had a net margin of 12.60% and a return on equity of 58.25%. The firm had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $171.92 million. During the same period in the previous year, the business posted $0.41 earnings per share. The company’s revenue for the quarter was up 15.1% compared to the same quarter last year.

A number of equities analysts have commented on CLB shares. Scotiabank set a $136.00 price objective on shares of Core Laboratories and gave the stock a “hold” rating in a research report on Wednesday, October 25th. Loop Capital reduced their price objective on shares of Core Laboratories from $125.00 to $115.00 and set a “buy” rating for the company in a research report on Wednesday, October 25th. ABN Amro raised shares of Core Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday, October 25th. Zacks Investment Research raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a research report on Wednesday, October 25th. Finally, UBS Group dropped their target price on Core Laboratories from $110.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, October 25th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $111.70.

Several institutional investors and hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its stake in Core Laboratories by 63.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,128 shares of the oil and gas company’s stock worth $114,000 after purchasing an additional 439 shares during the period. Robeco Institutional Asset Management B.V. raised its holdings in shares of Core Laboratories by 60.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 1,096 shares of the oil and gas company’s stock valued at $120,000 after acquiring an additional 414 shares in the last quarter. Advisory Services Network LLC raised its holdings in shares of Core Laboratories by 33.3% in the 2nd quarter. Advisory Services Network LLC now owns 1,365 shares of the oil and gas company’s stock valued at $138,000 after acquiring an additional 341 shares in the last quarter. Captrust Financial Advisors purchased a new stake in shares of Core Laboratories in the 4th quarter valued at about $139,000. Finally, Toronto Dominion Bank raised its holdings in shares of Core Laboratories by 243.6% in the 3rd quarter. Toronto Dominion Bank now owns 1,866 shares of the oil and gas company’s stock valued at $184,000 after acquiring an additional 1,323 shares in the last quarter.

Core Laboratories (NYSE:CLB) opened at $106.19 on Wednesday. The company has a current ratio of 1.98, a quick ratio of 1.66 and a debt-to-equity ratio of 1.53. Core Laboratories has a 52-week low of $86.55 and a 52-week high of $121.39. The company has a market cap of $4,700.41, a price-to-earnings ratio of 53.22 and a beta of 1.44.

The company also recently announced a quarterly dividend, which was paid on Friday, February 16th. Stockholders of record on Friday, January 26th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.07%. The ex-dividend date was Thursday, January 25th. Core Laboratories’s dividend payout ratio is currently 117.02%.

COPYRIGHT VIOLATION WARNING: “Core Laboratories (CLB) Expected to Announce Quarterly Sales of $171.06 Million” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/21/core-laboratories-clb-expected-to-announce-quarterly-sales-of-171-06-million.html.

Core Laboratories Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Get a free copy of the Zacks research report on Core Laboratories (CLB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply